Core Insights - The report published in The Lancet marks a significant milestone as it is the first major disease response strategy led by Chinese researchers in the journal's 200-year history [1] - The report highlights a critical shift in the causes of liver cancer, with metabolic dysfunction-related fatty liver disease (MASLD) and metabolic dysfunction-related steatohepatitis (MASH) emerging as significant contributors, alongside traditional causes like hepatitis and alcohol consumption [1] Group 1: Key Findings - The proportion of liver cancer cases related to MASH is projected to increase from 8% in 2022 to 11% by 2050, a 35% rise, particularly in developed countries [1] - Alcohol-related liver cancer cases are expected to rise from 19% to 21%, while hepatitis B and C-related liver cancer cases are projected to decrease from 39% and 29% to 37% and 26%, respectively [1] Group 2: Prevention and Management - The report indicates that at least 60% of liver cancer cases are preventable by reducing risk factors such as viral hepatitis infections, alcohol consumption, and controlling metabolic dysfunction-related fatty liver disease [2] - China bears 43% of the global liver cancer burden, but has made significant progress in prevention, notably through the introduction of the hepatitis B vaccine into the national immunization program since 2002, leading to a drop in infection rates among children [2] - The application of new diagnostic and treatment technologies at Fudan University Zhongshan Hospital has improved the five-year survival rate of liver cancer patients to over 70% [2]